Humira and Byetta get expanded CHMP extensions go-ahead
This article was originally published in Scrip
Abbott's Humira (adalimumab) is set to add ulcerative colitis to its roll call of inflammatory disease indications following a positive opinion from the EU's CHMP last week.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.